ストックスクリーナーアプリを入手
28.38
2.00%
-0.58
前日終値:
$28.96
開ける：
$28.86
24時間の取引高:
727.68K
Relative Volume:
0.48
時価総額：
$2.50B
収益：
-
当期純損益:
$-151.78M
株価収益率:
-13.78
EPS:
-2.0595
ネットキャッシュフロー:
$-136.42M
1週間 パフォーマンス:
+2.49%
1か月 パフォーマンス:
+19.44%
6か月 パフォーマンス:
-14.95%
1年 パフォーマンス:
+93.85%
1日の値動き範囲:
$27.69
$28.90
1週間の範囲:
$27.01
$31.11
52週間の値動き範囲:
$12.59
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
名前
Mineralys Therapeutics Inc
セクター
電話
(888) 378-6240
住所
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
28.38 | 2.50B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-27 | 開始されました | TD Cowen | Buy |
| 2025-06-11 | 開始されました | Jefferies | Hold |
| 2024-07-10 | 開始されました | H.C. Wainwright | Buy |
| 2024-04-02 | 開始されました | Goldman | Buy |
| 2023-03-07 | 開始されました | BofA Securities | Buy |
| 2023-03-07 | 開始されました | Credit Suisse | Outperform |
| 2023-03-07 | 開始されました | Evercore ISI | Outperform |
| 2023-03-07 | 開始されました | Guggenheim | Buy |
| 2023-03-07 | 開始されました | Stifel | Buy |
| 2023-03-07 | 開始されました | Wells Fargo | Overweight |
すべてを表示
Mineralys Therapeutics Inc (MLYS) 最新ニュース
Mineralys Therapeutics CMO Rodman sells $65,781 in stock By Investing.com - Investing.com India
Form 4 Mineralys Therapeutics Inc For: 10 July By Investing.com - Investing.com South Africa
Mineralys Therapeutics CMO Rodman sells $65,781 in stock - Investing.com UK
Mineralys Therapeutics (MLYS) CMO sells 2,171 shares after option exercise - Stock Titan
Mineralys (MLYS) reports 2,171-share exercise; Rodman sales listed - Stock Titan
Responsive Playbooks and the MLYS Inflection - Stock Traders Daily
Did Index Removal, ENDO 2026 Data and a $150M Raise Just Shift Mineralys Therapeutics' (MLYS) Investment Narrative? - simplywall.st
A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger - Yahoo Finance
Have Insiders Sold Mineralys Therapeutics Shares Recently? - simplywall.st
Have Mineralys Therapeutics Insiders Been Selling Stock? - Moomoo
Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential? - Insider Monkey
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) - 富途牛牛
Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing - marketscreener.com
Mineralys Therapeutics Insider Sold Shares Worth $1,960,601, According to a Recent SEC Filing - marketscreener.com
5 Best Up and Coming Pharmaceutical Stocks to Buy Now - Insider Monkey
Insider Sell: CEO Jon Congleton Sells 75,000 Shares of Mineralys Therapeutics Inc (MLYS) - GuruFocus
Form 4 Mineralys Therapeutics Inc For: 30 June By Investing.com - Investing.com Australia
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock - Investing.com
Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics CCO Eric Warren sells $2.7m in shares - Investing.com UK
Mineralys Therapeutics CEO Jon Congleton sells $1.96m in stock By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (MLYS) CEO sells 75K shares under Rule 10b5-1 plan - Stock Titan
Mineralys (NASDAQ: MLYS) CCO sells shares after option exercise - Stock Titan
Mineralys Therapeutics (MLYS) Form 144 lists 90,730 shares sold and RSU vesting - Stock Titan
Form 144 Mineralys Therapeutics For: 29 June By Investing.com - Investing.com Nigeria
Mineralys Therapeutics (NASDAQ: MLYS) flagged sale of 104,124 shares via cashless exercise - Stock Titan
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS:MLYS) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell Microcap Index - marketscreener.com
Mineralys Therapeutics, Inc.(NasdaqGS: MLYS) dropped from Russell 3000E Index - marketscreener.com
Enterprise value to EBITDA forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Price to earnings forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Understanding the Setup: (MLYS) and Scalable Risk - Stock Traders Daily
Price to sales forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
Price to book forward of Mineralys Therapeutics, Inc. – NASDAQ:MLYS - TradingView
What a $350,000 Insider Sale Might Mean for Mineralys Ahead of December FDA Decision - AOL.com
MLYS Forecast — Price Target — Prediction for 2027 - TradingView
Mineralys Therapeutics, Inc. Actuals & Estimates (NASDAQ:MLYS) - TradingView
Mineralys Therapeutics, Inc. Actuals & Estimates (BOATS:MLYS) - TradingView
Mineralys Therapeutics Inc (MLYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mineralys Therapeutics (MLYS) Edges Higher as Shares Hold Above Key SupportSign of Strength - Město Břeclav
Mineralys Therapeutics Inc (MLYS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mineralys Therapeutics Inc (MLYS) Institutional Confidence - TradingKey
Mineralys: Limited Differentiation Makes Lorundrostat A Weak Competitor - Seeking Alpha
Mineralys Therapeutics Inc (MLYS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mineralys Therapeutics Inc (MLYS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mineralys Therapeutics director Karydas sells $75,000 in stock By Investing.com - Investing.com India
Mineralys Therapeutics CMO Rodman sells $350,086 in stock By Investing.com - Investing.com India
Mineralys Therapeutics (MLYS) CMO sells 14,474 shares, exercises options - Stock Titan
Director at Mineralys Therapeutics (MLYS) trades 3,000 shares under 10b5-1 plan - Stock Titan
Mineralys Therapeutics Inc (MLYS) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):